Recent News

• 06.02.2025 - IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
• 05.30.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 05.06.2025 - IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.06.2025 - IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
• 04.28.2025 - IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
• 04.25.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 04.14.2025 - IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
• 04.10.2025 - IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
• 04.01.2025 - IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
• 03.31.2025 - IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Recent Filings

• 05.20.2025 - ARS Annual Report to Security Holders
• 05.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - 8-K Current report
• 04.30.2025 - DEF 14A Other definitive proxy statements
• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.02.2025 - 8-K Current report